Seroatlas · Human Serome Atlas

PRAMEF13

PRAME family member 13

Also known as: PRA13_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q5VWM6
Gene: PRAMEF13
Ensembl: ENSG00000279169
Chromosome: 1
Canonical length: 474 aa
Protein class: Predicted intracellular proteins

OverviewNCBI Gene

Predicted to enable ubiquitin-like ligase-substrate adaptor activity. Predicted to be involved in proteasome-mediated ubiquitin-dependent protein catabolic process. Predicted to be part of Cul2-RING ubiquitin ligase complex. Predicted to be active in cytoplasm. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

474 residues, UniProt reviewed canonical sequence.

>Q5VWM6|PRAMEF13
     1  MSIQAPPRLL ELAGQSLLRD QALSISAMEE LPRVLYLPLF MEAFRRRHFQ TLTVMVQAWP
    61  FTCLPLGSLM KTLHLETLKA LLEGLHMLLT QKDRPRRRKL QVLDLRDVDE NFWARWPGAW
   121  ALSCFPETMS KRQTAEDRPR MGEHQPLKVF IDICLKEIPQ DECLRYLFQW VYQRRGLVHL
   181  CCSKLVNYLT PIKHLRKSLK IIYLNSIQEL EIHNMSWPRL IRKLRCYLKE MKTLGKLVFS
   241  RCHHSTSDNE LEGRLVTKFS SVFLGLEHLQ LLKIKLITFF SGHLEQLIRC LQNPLENLEL
   301  TYGYLLEEDV KCLSQYPSLG YLKHLNLSYV LLFRISLEPL GALLEKIAAS LETLILEGCQ
   361  IHYSQLSAIL PGLSRCSQLT TFYFGRNCMS MGALKDLLRH TSGLSKLSLE TYPAPEESLN
   421  SLVRVNWEIF TPLRAELMCT LREVRQPKRI FIGPTPCPSC GSSLSEELEL HLCC

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PRAMEF13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.28
Highest tissue expression: 0.1 nTPM

Expression across tissuesHPA

Tissue

testis: 0.1 nTPM
adipose tissue: 0 nTPM
adrenal gland: 0 nTPM
amygdala: 0 nTPM
appendix: 0 nTPM
basal ganglia: 0 nTPM

Single-cell type

adipocytes: 0 nCPM
adrenal cortex cells: 0 nCPM
adrenal medulla cells: 0 nCPM
alveolar cells type 1: 0 nCPM
alveolar cells type 2: 0 nCPM
astrocytes: 0 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

cerebellum: 0.1 nTPM
cerebral cortex: 0.1 nTPM
pons: 0.1 nTPM
white matter: 0.1 nTPM
amygdala: 0 nTPM
basal ganglia: 0 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.89
gnomAD pLI: 0.29
gnomAD missense Z: -0.81

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 1% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

ubiquitin-like ligase-substrate adaptor activity

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PRAMEF13 as an antibody target. Whether an autoantibody or antibody against PRAMEF13 could matter depends on whether native PRAMEF13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PRAMEF13 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PRAMEF13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...